Daiichi Sankyo gears up for five ADC launches in 2026

#DaiichiSankyo #ADCs #ADClaunches #Enhertu #Datroway #breastcancer #Oncology #antibodydrugconjugates #trastuzumabderuxtecan #datopotamabderuxtecan #pertuzumab #earlystagebreastcancer #triplenegativebreastcancer #Ifinatamabderuxtecan #IDXd #TROPIONBreast05study #ADCtechnology
zurl.co/TySHW

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compare....

#Article in @MedComm_MC
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...

#ClinicalTrial

GeparPiPPa Phase II trial comparing neoadjuvant endocrine therapy in combination with the PI3K-Inhibitor Inavolisib

#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...

Enhertu + Pertuzumab in 1L HER2+ MBC: FDA Priority Review FDA grants Priority Review to Enhertu+pertuzumab as first line treatment for HER2+ MBC decision expected Q1 2026.

FDA Priority Review for Enhertu + Pertuzumab in first-line HER2+ MBC

@fda.gov

oncodaily.com/fda-approval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Enhertu #Pertuzumab #HER2 #MBC #BreastCancer

Tumori al seno, anticorpo coniugato in prima linea rallenta la malattia (Adnkronos) - Cala del 44% il rischio che il tumore del seno metastatico Her2 positivo progredisca grazie all’anticorpo farmaco-coniugato in prima linea trastuzumab deruxtecan in associazione a pertuzumab. E’ quanto emerge da uno de...

Tumori al seno, anticorpo coniugato in prima linea rallenta la malattia ... LEGGI TUTTO #Tumori #CancroAlSeno #Her2Positivo #Trastuzumab #Pertuzumab

Final Overall Survival Results from the APHINITY Trial Confirm Long-Term Benefit of Adjuvant Pertuzumab in Early HER2-Positive Breast Cancer - OncoDaily Final Overall Survival Results from the APHINITY Trial Confirm Long-Term Benefit of Adjuvant Pertuzumab in Early HER2-Positive Breast Cancer / APHINITY trial,

Final Overall Survival Results from the APHINITY Trial Confirm Long-Term Benefit of Adjuvant Pertuzumab in Early HER2-Positive Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #OS #APHINITY #Pertuzumab #BreastCancer #HER2

Pertuzumab: Efectos, Usos y Beneficios en el Tratamiento del Cáncer ¿Qué es Pertuzumab y cómo funciona en el tratamiento del cáncer? Pertuzumab es un anticuerpo monoclonal diseñado específicamente para tratar ciertos tipos de cáncer, principalmente el cáncer de mama HER2 positivo. Este medicamento se... The post…

Pertuzumab: Efectos, Usos y Beneficios en el Tratamiento del Cáncer #Pertuzumab #Cáncer #Salud